AFJK

Analyst Note: AFJK (Aimei Health Technology Co., Ltd)

Date: 2026-06-12 Price: $46.12

1. Structural Readiness

• State: Context-only.
• Conservative Entry: N/A (Setup invalidated).
• Aggressive/Pre-breakout Entry: N/A.
• Breakout Level: N/A.
• Current Price: $46.12.
• Extension: N/A.
• ATR Current: 25.2% (Extreme).
• Coil Classification: INVALIDATED. The price action and timeline slippage relative to the May 2026 target indicate the setup is no longer live. A "forming" coil requires the structure to be intact and price holding above support; here, the fundamental timeline support has eroded.

2. Thesis Layer

• Thesis Status: TACTICAL / SETUP-LED.
• Analysis: There is no named secular thesis active for AFJK as of this date. The company is not currently a growth leader in a secular trend, nor a deep value recovery play, because the primary catalyst (the merger with United Hydrogen) has not been confirmed as closed. The investment case cannot be built on a macro theme (e.g., "hydrogen energy boom" or "biotech innovation") because the entity has not successfully merged to execute that strategy. The name must be judged strictly on the quality of the remaining SPAC shell and the status of the target, neither of which presents a confirmed setup.

3. The Business

• Entity Type: Special Purpose Acquisition Company (SPAC).
• Business Model: The company was formed solely to enter into a merger, share exchange, or asset acquisition with one or more businesses. It does not currently operate a commercial business.
• Target Strategy: Management intends to target "small cap" companies in North America, Europe, and Asia Pacific focused on healthcare innovation, specifically biopharmaceuticals, medical technology/devices, and diagnostics (Evidence [E3], [E4], [E8]).
• Target Specifics: The definitive agreement was entered into on June 19, 2024, with United Hydrogen Group Inc. (Evidence [E2], [E12]).
• Financial Position (as of Sept 30, 2025):
• Cash in Bank: $2,979.
• Trust Account: $45,443,570.
• Working Capital Deficit: $2,749,480 (Evidence [E5]).
• Regulatory Status: The China Securities Regulatory Commission (CSRC) has been reviewing United Hydrogen's materials since August 12, 2024, requiring supplementary materials on several occasions (Evidence [E7]).
• Share Count: As of May 4, 2026, there were 3,166,332 ordinary shares issued and outstanding (Evidence [E11]).
• Current Status: Shareholders approved the combination on November 6, 2025 (Evidence [E10]). Management *expected* to close by May 2026 (Evidence [E6]). As of June 12, 2026, the merger has not been confirmed as consummated in the provided evidence, leaving the company in a limbo state between a shell and a merged entity.

4. Archetype and Conviction

• Archetype Candidate: Growth Leader (Hypothetical/Intended).
• *Fit Analysis:* The company *intends* to be a Growth Leader by acquiring a healthcare innovator. However, as of June 12, 2026, it does not fit this archetype operationally. It remains a shell with a failed or delayed transaction.
• Valuation Context: The Trust Account holds ~$45.4M. With ~3.17M shares outstanding, the implied trust value per share is approximately $14.33. The current price of $46.12 represents a significant premium to the trust value, suggesting the market was pricing in a successful merger that has not yet occurred.
• Conviction Stack:
• Thesis Strength: None (No active thesis).
• Evidence Quality: Mixed. Strong on the *intent* and *agreement* (2024-2025 filings), but weak on *execution* (2026 status).
• Structural Quality: Poor. The timeline has slipped significantly (from June 2024 agreement to May 2026 expectation, now June 2026 with no close).
• Setup Readiness: Invalidated. The "breakout" (merger close) has not fired.
• Rerating Potential: Low. Without a closed merger, the premium to trust value is unsupported.
• ATR Context: The current ATR of 25.2% is Extreme (>8%). Historically, this bucket correlates with the highest rate of severe losers or structural failures. This volatility is consistent with a SPAC facing a failed or delayed merger, where the price is decoupled from fundamentals and driven by binary event risk.

5. Invalidating/Strengthening Factors & Gaps

• What Would Invalidate:
• Confirmation that the merger with United Hydrogen has been terminated.
• A formal announcement of liquidation or return of trust funds to shareholders.
• Continued failure to close past the extended deadline without a new target.
• What Would Strengthen:
• A definitive announcement that the Business Combination with United Hydrogen has been consummated and the new entity is trading.
• Evidence of regulatory approval from the CSRC (previously noted as a hurdle in Evidence [E7]).
• Gaps in Evidence:
• Missing: Confirmation of the actual closing date of the merger as of June 12, 2026.
• Missing: Current financials post-September 2025 (specifically, has the working capital deficit been resolved?).
• Missing: Details on the CSRC review status as of mid-2026.
• Missing: Post-merger pro forma financials or operational metrics.

PRIVATE ANALYST CALL

Judgment: Sell Confidence: high Key evidence: 1. The setup is invalidated as the merger target date (May 2026) has passed without confirmation of closing. 2. ATR is 25.2% (Extreme), historically the highest risk bucket for severe losses. 3. Working capital deficit of $2.7M existed as of Sept 2025 with minimal cash on hand ($2,979), creating liquidity risk. 4. Price ($46.12) trades at a massive premium to Trust Value (~$14.33) without a confirmed merger to justify the valuation. Key risks: 1. Total loss of trust value if the SPAC liquidates. 2. Regulatory blockage by CSRC preventing the United Hydrogen merger. 3. Dilution from a new financing round to cover the working capital deficit. 4. Time decay of the trust account due to extended operational costs. Sizing hint: Position size should be zero; the structural setup is broken. Expected path: Management will likely announce a termination of the agreement or a new extension/liquidation process, causing the price to converge toward the trust value or lower. Expected horizon: Immediate to 30 days (until next regulatory or shareholder announcement). Failure mode to watch: A surprise announcement that the merger has closed and the new entity is operational, which would invalidate the "Sell" thesis.